Study S000996

A Phase 2, Randomized, Double-blind, Placebo-controlled, Study of the Safety and Tolerability of Aleniglipron in Adult Participants With Type 2 Diabetes Mellitus Living With Obesity or Overweight

ClinicalTrials.gov record

Registration

Registration: NCT07400588
Acronym: GSBR-1290
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 58
Start: 2025-12-01
Primary completion: 2026-09
Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Conditions: Obese; Obesity; Obesity Type 2 Diabetes Mellitus; Weight Loss
Interventions: DRUG:Aleniglipron; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Incidence, severity and relationship of AEs/SAEs [Baseline to week 31]
Assessment of vital signs [Baseline to week 31]
Assessment of laboratory measures [Baseline to week 31]
Assessment of Electrocardiograms (ECG) [Baseline to week 31]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.